Clinical Trial Update: A Pilot Study of High-Dose Omega-3 (Soloways ™) Polyunsaturated Fatty Acids in Patients with Dyslipidemia Carrying FADS1/FADS2 Variants [NA]

View source ↗

Summary

A completed pilot trial evaluating high-dose Soloways omega-3 polyunsaturated fatty acids in patients with dyslipidemia carrying FADS1/FADS2 gene variants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• Soloways Omega-3 Polyunsaturated Fatty Acids (Omega-3 fatty acids (EPA/DHA))

Snippet

Sponsor: S.LAB (SOLOWAYS) | Conditions: Dyslipidemia | NA | Status: COMPLETED